Welcome to our dedicated page for Koninklijke Phil news (Ticker: PHG), a resource for investors and traders seeking the latest updates and insights on Koninklijke Phil stock.
Koninklijke Philips N.V. reports health technology developments across Diagnosis & Treatment, Connected Care and Personal Health. News from Royal Philips commonly covers order intake and comparable sales trends; product launches and regulatory clearances for imaging, image-guided therapy and AI software; and governance actions from its Annual General Meeting. Recent product themes include CT platforms such as Rembra and Spectral CT Verida, interventional guidance tools such as DeviceGuide and IntraSight Plus, and the Bridge Plus Occlusion Balloon for lead extraction procedures.
The company’s updates also address hospital monitoring, informatics, ultrasound, oral health and personal-care lines. Coverage reflects Philips’ role as a Netherlands-based global health technology company with securities traded on NYSE under PHG and on Euronext Amsterdam under PHIA.
KONINKLIJKE PHILIPS N.V. announced the results of its tender offers for its outstanding Euro notes, with a total of €196,976,000 in 2023 Euro Notes, €224,535,000 in 2024 Euro Notes, and €154,471,000 in 2025 Euro Notes validly tendered. The company intends to accept all validly tendered Existing Notes without pro-ration. The maximum acceptance amount for the offers is set at €230,193,677.02. Settlement is expected on 10 May 2022. Existing Notes not accepted will remain outstanding, and the company plans to redeem them post-settlement.
Royal Philips announced the results of its tender offer for its outstanding debentures. As of the May 5, 2022 expiration time, approximately $20.86 million in aggregate principal amount was validly tendered and not withdrawn. No notes were tendered under guaranteed delivery procedures. The settlement date for accepted notes is expected to be May 10, 2022, with holders receiving accrued interest. The offer impacts the 2025 Series A, 2025 Series B, and 2026 Notes, with specific principal amounts tendered detailed in the release.
Royal Philips has announced the pricing terms for its cash tender offer to purchase its outstanding 71/8% Series A Debentures, 73/4% Series B Debentures, and 7.200% Notes. The final deadline for holders to tender their notes is 5:00 p.m., New York City time, on May 5, 2022. Accepted holders will receive applicable consideration plus accrued interest. The offer is subject to financing conditions, with settlement expected on May 10, 2022.
Royal Philips (NYSE: PHG) is showcasing its integrated solutions for stroke care at the ESOC 2022 conference, aimed at enhancing diagnostic confidence and reducing treatment time. The company emphasizes the urgent need for optimized workflows in stroke care, as timely treatment is vital for patient outcomes. Key offerings include advanced imaging technologies like the Spectral CT 7500 and ePatch for continuous ECG monitoring. Philips is also sponsoring the WE-TRUST trial to compare traditional and Direct to Angio Suite approaches in stroke treatment, which aims to lower costs and minimize disability.
Royal Philips (NYSE: PHG) announced the successful pricing of EUR 750 million fixed rate notes due 2027, EUR 650 million Green Innovation Notes due 2029, and EUR 600 million Sustainability Innovation Notes due 2033 under its European Medium Term Note (EMTN) program.
The net proceeds will fund Eligible Projects as per Philips' Green and Sustainability Innovation Bond Framework, with a portion allocated to general corporate purposes. The company plans to optimize its treasury liquidity profile through liability management, including tender offers for outstanding bonds and share buyback programs.
Royal Philips (NYSE: PHG) has entered a multi-year agreement with Prisma Health, South Carolina's largest health system, to enhance patient monitoring and enterprise imaging. This partnership aims to promote interoperability and data analytics, contributing to the Quadruple Aim of healthcare: improving patient and staff satisfaction while lowering costs. Prisma Health, with nearly 3,000 licensed beds and over a million unique patients treated annually, will become the largest North American installation of Philips' Performance Bridge analytics platform for monitoring healthcare delivery.
Royal Philips has initiated a cash tender offer for its outstanding Notes including 71/8% Series A Debentures, 73/4% Series B Debentures, and 7.200% Notes. The offer expires on May 5, 2022, and will allow holders to tender any and all of the specified Notes. Additionally, Philips plans to issue new euro-denominated notes and may redeem existing Euro Notes. The company aims to cancel approximately 28.3 million shares as part of its capital return strategy. Investors should note that the offer is subject to a financing condition.
Summary not available.
Philips reported first-quarter 2022 sales of EUR 3.9 billion, reflecting a 4% decline compared to Q1 2021. The company experienced a significant loss of EUR 152 million from continuing operations, worsening from a loss of EUR 34 million in the previous year. Adjusted EBITA dropped to 6.2% of sales. Despite challenges, including supply chain issues and the Respironics field action, order intake rose by 5%. Notably, Personal Health sales grew by 8%. Philips anticipates further growth in 2022 but acknowledges risks from geopolitical tensions and inflation.
Royal Philips (NYSE: PHG) has announced a notification regarding potential issues with its V60/V60 Plus and V680 ventilators manufactured by its subsidiary, Philips Respironics. The electrical circuit controlling the 35V power supply may cause silent shutdowns, risking respiratory assistance for patients. Philips recommends mitigation actions such as using an oxygen analyzer and ensuring alternative ventilation is available. The FDA has classified the recall as Class 1 in the U.S. Philips is committed to safety and will provide updates by June 30, 2022.